Botanix Pharmaceuticals in North Perth, Western Australia | Medical and health

Botanix Pharmaceuticals

Locality: North Perth, Western Australia

Phone: +61 8 6555 2945

Address: Level 1, 50 Angove Street 6006 North Perth, WA, Australia

Website: https://www.botanixpharma.com/

Likes: 658

Add/Update information

Reviews

Tags

• Medical and health

25.01.2022 An independent report recently published by Euroz Hartleys provides insightful commentary into Botanix’s advanced development pipeline and platform technology. The author noted: The company is looking to shake up big markets in dermatology and antimicrobials with its four clinical programs (target indications: acne, antimicrobial, rosacea and atopic dermatitis) which leverage the unique anti-inflammatory, immune modulating and antimicrobial properties of synthetic cannabinoi...d, in conjunction with an exclusively licensed proprietary drug delivery system Permetrex. We believe the stock will trade up as the market begins to better understand the potential of BOT’s programs, we anticipate this will occur as we near the multiple catalyst due early to mid-next year. Read the full report bit.ly/BOT_EurozHartleys $BOT #ASX #research #innovation #CBD #syntheticCBD

24.01.2022 IN THE NEWS The Green Fund has published a summary of our announcement today, an update on the development pathway for our BTX 1801 antimicrobial product. Take a look https://bit.ly/BOT_GF

24.01.2022 NEW APPOINTMENT Botanix Pharmaceuticals is pleased to welcome Dr Jack Hoblitzell to the team as Senior Vice President of Pharmaceutical Development. Dr Hoblitzell brings over 30 years of extensive experience in leading world-class technical operations, manufacturing and supply chain management. He has held senior leadership roles in the US with companies including Pfizer, King Pharmaceuticals, Ivax Pharmaceuticals and Teva Pharmaceuticals, where he led numerous successf...ul new product launches and regulatory submissions. Vince Ippolito, President and Executive Chairman, commented: We are pleased to welcome Jack to the Botanix team. His depth of experience and success in leading successful new product launches and regulatory submissions will be invaluable as we continue to focus on our clinical programs as they move into last stage studies and commercial manufacturing, as well as our increasing work with the Permetrex platform. Read the announcement here https://bit.ly/BOT_JackHoblitzell $BOT #ASX #research #innovation #biotech #pharma #CBD #syntheticCBD #leadership

21.01.2022 IN THE NEWS The Market Herald has published an article titled, "Botanix Pharmaceuticals (ASX:BOT) gets U.S. FDA clearance for BTX 1801 development." Take a look here https://bit.ly/BOT_MH

20.01.2022 IN THE NEWS 'Superbugs will kill 22,000 Australians annually by 2040; but these stocks are trying to stop that' - writes Nick Sundich from Stockhead. Botanix is featured in this wrap up of ASX-listed stocks leading the way to address the threat of superbugs.... Take a look https://bit.ly/BOT_StockHead

17.01.2022 DERMATOLOGY UPDATE Botanix is pleased to announce the launch of our BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. This will enrol 45 canines and evaluate two formulations of BTX 1204A. Positive data from our pilot study in May has already demonstrated that a new higher dose of synthetic CBD, in a novel Permetrex formulation, reduces severity of atopic dermatitis over 28 days - providing strong foundations for us to extend this program into bot...h animal and human health. Our BTX 1702 rosacea study is also gaining momentum. We are on track to enrol 120 patients in Australia and New Zealand, which will investigate the safety and tolerability of two different concentrations of BTX1702. Read today’s announcement here https://bit.ly/BOT_Derm_Update $BOT #ASX #research #innovation #biotech #pharma #CBD #syntheticCBD

13.01.2022 IN THE NEWS The Motley Fool's Aaron Teboneras featured Botanix Pharmaceuticals as a top stock pick in an article titled, Why I think these small cap ASX shares will perform in 2021. Here’s a highlight:... At the time of writing, the Botanix share price is trading at 10 cents, up 7.5% for the day. With a market capitalisation of $97 million, if the company can perform to market expectations, its share price will soar. Read the full article here http://bit.ly/BOT_MotleyFool #AMR #dermatology #biotech #pharma #innovation

12.01.2022 Botanix Pharmaceuticals Executive Director, Matt Callahan, spoke with Stockhead yesterday about the global threat of antimicrobial resistance: The alarm bells have been going off the last five years (on antimicrobial resistance), but no one’s really believed that the global economy could be stopped and millions and millions of deaths could be caused by some kind of pathogen but of course I think we all believe that now, sadly, he said. Read the full article here http://bit.ly/BOT_Stockhead_AMR

11.01.2022 BOT QUARTERLY REPORT Botanix Pharmaceuticals has released its latest Quarterly Report a period which has delivered a series of progress milestones. In our antimicrobial program, we commenced a Phase 2a clinical trial for BTX 1801 to study the use of synthetic cannabidiol in the prevention of surgical site infections. We also shared new data from an ex vivo efficacy study, which further validates the mechanism of action of our antimicrobial platform.... In our dermatology program, we successfully completed an End of phase 2 meeting with the FDA for our BTX 1503 acne product. We’re also looking forward to commencing recruitment for our BTX 1702 program for the treatment of Rosacea, when COVID-19 travel restrictions ease. Read the full report here http://bit.ly/BOT_QuarterlySep

10.01.2022 The Australian Government Department of Health has this week published a summary of funding and strategy measures announced to address antimicrobial resistance (AMR) in the recent 2020-21 Federal Budget. This includes $22.5m to address the priorities identified in 'Australia’s National Antimicrobial Resistance Strategy 2020 & Beyond'. We welcome support from the Australian Government as we develop our BTX 1801 antimicrobial pipeline and are committed to active and collabo...rative participation in the whole-of-industry response needed to address this pressing global health emergency, said Botanix Pharmaceuticals’ President and Executive Chairman, Vince Ippolito. Read the summary here https://bit.ly/BOT_AMR

10.01.2022 IN THE NEWS Thanks for sharing this article AusBiotech - we are optimistic about the path ahead for our #Antimicrobial pipeline. https://biotechdispatch.com.au//botanix-pharmaceuticals-up

07.01.2022 "Is this just a projection...?" The narrator of this video asks, as she examines the possibility of a world devoid of effective antibiotics, a most precious resource. Due to "use, misuse, overuse" of antibiotics, a dire future is forecast. It is thought provoking, unnerving - but also deeply motivating to be part of global action to address antimicrobial resistance (AMR).... Here at Botanix, we are committed to developing novel solutions to address AMR through our BTX 1801 pipeline. In World Antimicrobial Awareness Week (#WAAW) it’s encouraging to see this vital conversation gaining momentum too. Watch the video here https://bit.ly/BOT_AMRVideo

06.01.2022 FEATURE ARTICLE Botanix has appeared in a must-read feature about antimicrobial resistance (AMR) in the latest edition of AusBiotech's Australasian Biotechnology Journal. It is titled, Antimicrobial resistance: a global health emergency.... A quote from WHO Director-General Dr Tedros Adhanom Ghebreyesus, featured in the story, points to the importance of the work we are doing in this space: AMR is a slow tsunami that threatens to undo a century of medical progress. A record number of countries are now monitoring and reporting on antibiotic resistance to WHO. Read the full story on pages 52-54 http://bit.ly/BOT_AusBiotech #AMR #cbd #innovation #biotech #pharma #AusBiotech

05.01.2022 BTX1801 UPDATE Botanix has today announced it has secured a clear development path from the FDA for our BTX 1801 synthetic cannabidiol antimicrobial product, following the successful completion of a Pre-Investigational New Drug (Pre-IND) meeting. We’ll have more clinical data to share soon too our BTX 1801 Phase 2a study in Perth is fully enrolled and remains on track for completion before the end of this calendar year.... Read today’s ASX release https://bit.ly/BOT_FDAPath

05.01.2022 IN THE NEWS Two US lawmakers have introduced a bipartisan bill to create a new payment model to encourage drug developers to develop new classes of antibiotics. It’s called the PASTEUR Act, which will facilitate upfront payments to companies in exchange for unlimited access to their antibiotics. In turn, drug makers can recover their costs and turn a profit, before selling large volumes of product. ... Relevant extracts include: An antimicrobial drug developer can apply to receive a ‘critical need antimicrobial’ designation Contracts will range from $750 million to $3 billion and will be paid out over a period of up to 10 years or through the length of patent exclusivity Botanix Pharmaceuticals wholeheartedly welcomes this news. As we enter a critical period of R&D for our BTX 1801 antimicrobial resistance (AMR) platform, this is a significant endorsement of the immediate need for novel antibiotics and further evidence of the world’s most powerful pharmaceutical influencers prioritising expedited and significant expenditure in this space. You can read a summary of the bill here http://bit.ly/BOT_AMRBill #AMR #superbugs #PASTEURAct

04.01.2022 Today marks the start of World Antimicrobial Awareness Week (#WAAW). According to the World Health Organization (WHO) this initiative ‘aims to increase awareness of global antimicrobial resistance (AMR) and to encourage best practices among the general public, health workers and policy makers to avoid the further emergence and spread of drug-resistant infections.’ As developers of a novel AMR solution, to first target surgical site infections (SSIs), Botanix is proud to supp...ort this important week of advocacy and education. Learn more https://bit.ly/BOT_AMRWeekWHO

04.01.2022 BOTANIX PEOPLE Meet Dr Ira Lawrence, MD, FACP Medical Consultant... For over 30 years, Dr Ira Lawrence has been at the forefront of research and development within the pharmaceutical and medical devices industries. A Board-Certified Internist, Clinical Immunologist and fully-licensed Physician, Ira is Botanix’s first line of expertise when it comes to seeking clinical and regulatory advice for clinical and pre-clinical programs. Well versed in regulatory affairs, Ira has been involved in the development and approval processes of numerous ‘first in class’, ‘best in class’ and market leaders for dermatologic, immunologic and infectious disease products and devices. He is impressed with Botanix’s focus on the use of CBD in areas of unmet clinical need. Botanix recognises the tremendous potential benefits of this new class of drugs for its clinical efficacy and excellent safety profile, he said. He believes that with any new compound, but especially those which have captured the imagination of the public, it is essential that the clinical benefits and safety of those products are rigorously demonstrated. To me, Botanix is advancing the promise of ‘CBD through science’ by its strong commitment to conducting well-designed and well-managed clinical trials to demonstrate the efficacy and safety of its CBD-based products. #innovation #biotech #pharma #leadership #CBD

01.01.2022 PROACTIVE VIDEO Botanix President and Executive Chairman, Vince Ippolito, was interviewed by Christine Corrado at Proactive’s New York studio yesterday. Their conversation focused on the recent launch of our BTX 1204A canine study for atopic dermatitis and our BTX 1702 rosacea study in Australia and New Zealand.... In commenting on the potential for the atopic dermatitis study, Vince said: A successful outcome for this study could lead to partnering opportunities for Botanix in animal health a $750m dollar market. As well as back into another Phase2b study in humans for atopic dermatitis. Watch video interview here https://bit.ly/BOT_ProactiveIV $BOT #ASX #research #innovation #biotech #pharma #CBD #syntheticCBD